420 with CNW — White House FAQ Reveals That Prospective Interns Will Be Asked About Past Cannabis Use

Earlier this week, the Biden Administration announced that individuals who would like to intern at the White House would be required to disclose any previous drug use. This is despite repeated requests to stop penalizing employees who admit to past use of cannabis.

A new White House Internship program FAQ states that applicants going through the hiring process will be required to fill out a security clearance form. The data collected by this form may affect the eligibility of the candidates, especially if it includes information on past consumption of marijuana, even if it was legal under state law.

In the early days of this administration, the Biden White House was criticized over reports that staffers were being penalized or terminated on the basis of past cannabis use. President Biden has been against marijuana’s legalization for some time now, with a former White House press secretary reiterating that the president hadn’t changed his stance on maintaining federal prohibition soon after Senate Majority Leader Chuck Schumer and his colleagues introduced a draft bill to legalize cannabis in 2021.

However, while campaigning in 2020, Biden ran on a pledge to enact reforms such as the expungement of previous records, the decriminalization of marijuana possession and respecting the rights of states to enact their own laws.

Since the president assumed office, the administration has made no strides to enact any of these changes, instead choosing to fire its staffers over cannabis and extending a provision that prevented D.C. from legalizing the sale of marijuana.

Results from a poll released earlier in January show that more than one-half of Americans feel that the president has made little progress on his pledge to decriminalize cannabis in his first year in office, with most individuals expecting that little will be done to advance reform as his term continues. The president has received numerous letters from advocates, legislators, celebrities and individuals affected by criminalization, calling on him to do something about the individuals who are still behind bars over marijuana.

While Biden has granted clemency to some individuals with nonviolent federal drug convictions on their records, not much else has been done. This is despite findings from a report by the Congressional Research Service showing that Biden has the power to grant mass pardons for marijuana offenses.

For her part, Vice President Kamala Harris stated in 2021 that the administration wasn’t focused on making progress on its cannabis reform pledges because it was overburdened with other issues.

It is this inaction at the highest level of government that is holding back the marijuana industry and entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) from growing their footprint across the country as quickly as they would desire.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — The Do’s and Don’ts as Thailand Eases Marijuana Restrictions

Thailand has become the first country in Asia to decriminalize the cultivation and sale of marijuana. However, Thai residents won’t be living in a recreational cannabis paradise anytime soon.

The Asian country plans on enacting strict cannabis policies and tough penalties for anyone caught indulging in recreational weed. According to Thai Health Minister Anutin Charnvirakul, the move is meant to boost Thailand’s economy by tapping into the billion-dollar medical cannabis industry.

Anutin cautions against using cannabis recreationally as the country still has laws that control the consumption of marijuana products in a “nonproductive” way. Rather than launch a recreational market, Thailand’s new cannabis laws will allow citizens to grow and sell cannabis and hemp products.

Restaurants will also be allowed to stock and serve cannabis-infused drinks and foods as long as the product contain less than 0.2% of delta-9 tetrahydrocannabinol (THC). This is the main component in marijuana that makes users feel “high.” Hemp, which is virtually identical to cannabis except for its THC levels, has minimal to no THC.

Thailand’s cannabis policies will mainly be centered on medical marijuana. Already allowed by dozens of territories around the world, medical marijuana has been found to have potential in treating a variety of medical conditions.

Anutin says the country has no plans to be a recreational cannabis haven for tourists either, stating that Thailand will only promote medical cannabis policies. Tourists who wish to purchase medical cannabis products are free to visit, but those coming to indulge in adult-use cannabis are not welcome, he says.

Thailand is known for its tough anti-drug laws. As it stands, the Public Health act levies a punishment of up to three months in jail and a fine of $800 for lighting up in public. According to Anutin, the government has never considered legalizing cannabis for recreational consumption or to be used in ways that could “irritate others.”

The Public Health Ministry also announced that more than 3,000 inmates who were imprisoned for hemp- and cannabis-related drug offenses will soon be released. In wake of the legalization news, marijuana advocacy group Highland Legalization has organized a weekend festival that will involve panel discussions, musical performances and cannabis food sales.

However, some activists are still apprehensive about Thailand’s new cannabis policies as law enforcement hasn’t been as quick to adapt to changing laws. Thailand first decriminalized medical cannabis use in 2018 and has been steadily loosening its cannabis laws under Anutin’s watchful eye.

However, law enforcement hasn’t always kept up with these changes. A few weeks ago, a 56-year-old woman in eastern Chonburi Province who had diabetes and high blood pressure was arrested by plainclothes police officers after they saw a potted cannabis plant in her bedroom. Anutin states that the four officers have already been disciplined. He adds that the government will need to educate both law enforcers and ordinary citizens about the evolving cannabis laws.

As the strict marijuana laws around the region begin to loosen, an opportunity may be created for established cannabis companies such as Flora Growth Corp. (NASDAQ: FLGC) to expand into these emerging markets.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
The pre-IND meeting will confirm the details of the company’s IND-enabling program
Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

According to the September 8 news release, Lexaria had retained the services of an expert regulatory affairs and quality assurance consulting group that would help prepare the company for a pre-IND meeting with the FDA. The group would also assist Lexaria with designing the requisite non-clinical, clinical, and related product development IND-enabling work/program meant to be finalized before the company files its IND application.

Through the intervening period, Lexaria has made progress bringing it closer to achieving these goals, recently reporting it had filed a pre-IND meeting request letter with the FDA. The request, to which the federal agency had already responded and set a target date of July 30, 2022 (subject to the fulfillment of certain conditions), formally initiated communication with the FDA concerning the development of DehydraTECH-CBD as a treatment for hypertension (https://cnw.fm/SNVqc).

“We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” commented Lexaria President John Docherty. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.”

The pre-IND meeting is intended to confirm the details and acceptability of Lexaria’s IND-enabling work, which is set to be completed after the meeting has been held. This work has been made possible by the company’s growing body of evidence showing DehydraTECH-CBD’s capacity to potentially treat hypertension.

Through its successfully completed studies – HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3 – Lexaria has not only demonstrated that DehydraTECH-CBD lowers the human blood pressure relative to placebo and reduces arterial stiffness but also that it does not cause any adverse effects. According to the company’s recent statement, efficacy and the lack of negative side effects are the two main goals of FDA-registered clinical studies.

Following the pre-IND meeting and the completion of the IND-enabling development program, Lexaria expects to then proceed with its full IND application filing expected in late 2022 or early 2023.

Meanwhile, the company also celebrated another milestone that saw it expand the list of licensees. In a recent announcement, Lexaria reported that its wholly owned subsidiary, Lexaria Pharmaceutical Corp., had awarded a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland (https://cnw.fm/ZrHuV).

The license allows AnodGen, a newly established contract manufacturing organization business, to manufacture and distribute DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe (including the UK), Australia, and New Zealand. The license also covers pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen can also manufacture and sell the API powders to third-party companies for their own products, subject to the fulfillment of specific conditions. On its part, Lexaria will receive royalty fees for all API powders sold that utilize the DehydraTECH drug delivery technology.

This licensing agreement comes on the heels of two similar agreements that saw Lexaria Pharmaceutical Corp. grant a European and UK license to medical cannabis manufacturer Valcon Medical A/S (https://cnw.fm/eHkdp) and a license to Premier Wellness Science Co. Ltd to deploy DehydraTECH within the Japanese non-pharmaceutical market (https://cnw.fm/cfkkH).

“We are focused on larger national and international applications for DehydraTECH, primarily but not entirely in the pharmaceutical sector. These are our areas of interest that we expect will provide significant revenue streams over time…,” commented Lexaria CEO Chris Bunka in a January letter to shareholders (https://cnw.fm/pcj9E). With the series of out-licenses announced recently, Lexaria appears to be inching closer to realizing this goal.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Senator Asks Congress to Allow Cannabis Businesses to Access Business Loans

America’s cannabis industry exists in a sort of limbo. Although dozens of states now allow the cultivation and sale of cannabis to adults aged 21 and older, federal law still outlaws the plant and considers it a Schedule I controlled drug.

This means that even though licensed cannabis businesses are seen as legal commercial enterprises by many states, they cannot access many of the services other industries enjoy. One such service is benefits and grants from the federal government. Cannabis businesses felt this most acutely during the coronavirus pandemic when the national government deployed aid funds to businesses through the federal Small Business Administration (SBA) loans program, but federal law prevented the cannabis companies from accessing much-needed funds.

Senator Jacky Rosen is now requesting that marijuana businesses be granted access to SBA loans as well as other federal resources via an impending spending bill. A persistent supporter of the cannabis industry’s right to access SBA resources without any restrictions, the senator sent a letter to the Senate Appropriations Committee. She requested that language preventing the SBA from denying small cannabis businesses federal loans be added to the Financial Services and General Government Related Agencies Appropriations Bill for fiscal year 2023.

This language would allow state-legal cannabis businesses to access loans from the Disaster Assistance Program, Microloan Program, Loan Guarantee Program and the 504/Certified Development Company Loan Program. The letter also requests that state-legal cannabis businesses be allowed to participate in the Small Business Administration’s entrepreneurial development programs.

The Nevada senator noted that states are now seeing billions of dollars’ worth of cannabis sales and the numbers are expected to rise as even more states move to legalize either recreational or medical cannabis in 2022.

But despite the fact that the cannabis businesses pay billions of dollars in taxes, SBA policy currently excludes businesses that directly or indirectly deal with cannabis from its entrepreneurial development and loan programs. This locks out cannabis businesses as well as enterprises outside the industry that choose to take advantage of the extremely profitable cannabis industry.

Rosen also raised the issue last year during a Senate Small Business and Entrepreneurship Committee hearing during which SBA administrator Isabel Guzman said she would look into granting cannabis businesses access to SBA loans.

Last July, Rosen and nine other senators penned a letter to the leadership of the Senate Appropriations Committee requesting that marijuana businesses be allowed to access federal Small Business Administration loans.

If access to this funding is granted, the sector would grow more steadily and more companies as well as individuals may be interested in giving advanced cultivation equipment such as the grow containers made by Advanced Container Technologies Inc. (OTC: ACTX) and similar companies a try.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Concludes Cannabis Is Safe, Effective in Treating Cancer Pain

Israeli researchers recently published a scientific paper proving that cannabis has the potential to provide chronic pain relief to patients undergoing cancer treatment. Such patients are typically prescribed pharmaceutical painkillers to manage their pain during treatment. But while these drugs can be effective at reducing pain, they tend to cause adverse side effects such as addiction.

Researchers have been on the lookout for a drug that can provide the same pain relief without any of the side effects for quite a while. The paper notes that while medical cannabis can also have side effects, those effects can be categorized as “mild to moderate” and are generally well tolerated.

The study authors state that there were relatively few small-scale studies on marijuana’s pain-relief abilities before they ran their study, which involved 404 cancer patients. The patients were prescribed an initial dose of 20 grams of medical cannabis a month that could either be smoked or taken as an oil extract. They were asked to answer questions about their cancer treatment symptoms before treatment began and at certain points during the entire six-month study.

The paper, which was published in the journal “Frontiers in Pain Research,” states that total cancer symptoms were reduced by an 18% average rating while average weekly pain intensity dropped by a 20% median. Furthermore, the patients didn’t need to increase their dosages during the six months for the cannabis to be effective. In total, 40% of the patients stopped using pharmaceutical analgesics after the study concluded.

However, 20% picked up their analgesic use after the study while 25% of the patients reported that their pain increased in intensity after they stopped the cannabis treatment. The researchers posit that the patients who didn’t need to go back to pharmaceutical pain killers after the study had “less severe disease” and thus had fewer comorbidities by the time the study wrapped up.

Their conclusion was that cannabis has the potential to provide “mild to modest long-term improvement” in cancer-associated symptoms, including pain. Most importantly, the paper states, it can lead to a reduction in the use of opioids and other analgesics that aren’t always risk free. However, the study authors note that survival bias may have affected their results and that medical cannabis may have “limited efficacy and clinical relevance.”

Technion Israel Institute of Technology and study coauthor David Meiri says we will need future studies to investigate how effective medical cannabis can be when used by patients with specific types of cancer and specific shared characteristics.

As the therapeutic potential of cannabis is affirmed by more scientific studies, the products made by companies such as American Cannabis Partners are likely to gain broader public trust, and consumption habits could ultimately be shaped by the information about the medicinal benefits of these substances.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”

To view the report, visit https://cnw.fm/yJy9P

To view the full press release, visit https://cnw.fm/U1F9I

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and is dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — How Patients Can Access Free Medical Cannabis in California

By the start of 2022, more than 30 states had legalized medical marijuana. Research has found that cannabis can be quite effective at alleviating medical conditions such as chronic pain, insomnia and post-traumatic stress disorder (PTSD). However, medical marijuana isn’t always cheap; according to Americans for Safe Access executive director Debbie Churgai, the number-one barrier to medical cannabis access is affordability.

Furthermore, federal prohibition means that insurance providers do not provide coverage for medical cannabis even if it is prescribed by a doctor. This often leaves those who need medical marijuana the most with no affordable way to access it.

In the state of California, however, in-need patients have been receiving free medical cannabis thanks to a partnership between marijuana delivery service Eaze, nonprofit groups and cannabis brands. The Eaze Compassion program has been offering free products to in-need medical cannabis patients since late 2019 and has handed out more than 100,000 THC-infused products in that period.

The program currently makes free home deliveries to patients living in San Jose, the Bay Area, Sacramento and the Greater Los Angeles area. Charlene Modeste, an LA native who lives with uterine fibroids, has been receiving thousands of dollars’ worth of cannabis products for free every few months from Eaze.

She learned about the Eaze Compassion program after contacting Dear Cannabis, a Sacramento-based organization that acts as a middleman between product-donating cannabis companies and compassion programs. Dear Cannabis connected Modeste to one of Eaze Compassion’s partners, an L.A-based nonprofit called This is Jane Project, which verified that she was eligible for the program and sanctioned the free deliveries.

Eaze also works with the Weed for Warriors Project, Operation EVAC (Educating Veterans About Cannabis), Bay Area Americans for Safe Access and other groups to facilitate compassionate deliveries to in-need patients. Eligibility for the program is determined through criteria such as medical diagnosis, need and income.

The cofounder and chief executive of veteran support group Weed for Warriors Project says access to affordable medical cannabis can save lives. Veterans who were overdrinking drank less when marijuana was available, he says, and there has been a noticeable reduction in overdoses, domestic violence and suicides since cannabis was made available to the veteran community.

Weed delivery company Eaze handles the deliveries while its partner organizations evaluate prospective patients. Medical cannabis patients who live within the delivery areas and would like to join the Eaze Compassionate program can reach out to any of the partner organizations and compassionate programs listed here.

Such programs to help patients in need show how diverse the benefits of allowing companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) to operate can be.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — U.S. Mayors Pass Measure Urging Congress to End Cannabis Prohibition

Earlier this week, the U.S. Conference of Mayors approved a resolution that would protect banks which work with state-legal cannabis businesses from federal penalties. This organization representing mayors passed the measure during its 90th annual meeting. In 2021, the body adopted a different resolution that promoted social equity in the growing marijuana industry and called for an end to federal marijuana prohibition.

This latest measure expresses support for federal measures to legalize marijuana, including the Cannabis Administration and Opportunity Act, which is being finalized in the Senate, and the Marijuana Opportunity, Reinvestment and Expungement Act (MORE Act), which was approved by the House.

This comes as Congress debates about whether to include the SAFE Banking Act as part of the America COMPETES Act, which is currently in negotiations in bicameral conference.

The mayors’ proposal states that the illegality of marijuana under federal law and the conflict it creates between federal law and state law has created significant barriers and challenges for legally operated and owned medical and recreational marijuana dispensaries and marijuana-related firms.

It also explains that marijuana firms aren’t able to access banking services that insurers and financial institutions provide to other businesses due to the possible civil and severe criminal penalties that these institutions may incur. This, it adds, has forced most companies to operate on a cash-only basis leading to an increase in targeted crime.

To resolve this, the mayors urge Congress to approve the SAFE Banking Act to not only enhance public safety but also offer financial security for marijuana dispensaries and related companies. Mayors of Henderson, Nevada; Fort Lauderdale, Florida; and Tacoma, Washington, sponsored the measure for the conference. This organization represents 1,400 cities in America, with populations of more than 30,000 individuals each.

Many hope that the SAFE Banking Act will be attached to the large-scale manufacturing bill in the interest of public safety and economic competitiveness. This measure, which has been approved in the House six times, is yet to be approved in the Senate.

Senate leadership is currently working to finalize a measure that would put an end to the federal prohibition of cannabis, and you can be sure that the entire cannabis industry, including companies such as Flora Growth Corp. (NASDAQ: FLGC) will be following all those federal legalization efforts.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) GrowPods Address Food Security Issues

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, along with related equipment and supplies, provide an effective way for food to be produced locally, almost anywhere in the world, thus enhancing food security. According to the announcement, the pandemic and disruptions to the food supply chain have heavily effected food supply around the world, with growing numbers of communities experiencing empty shelves. Consequently, governments and community groups are searching for ways to increase food supplies. Modular hydroponic farms, such as ACTX’s GrowPods, are a viable option. The company noted that its GrowPods can be used virtually anywhere and can produce the equivalent of three acres of traditional farmland in an automated environment, which can be monitored and controlled remotely. “These modular hydroponic farms can provide healthy food where it is needed, and offer sustainability benefits such as cutting freight emissions and shipping costs associated with transporting food long distances, reducing water consumption, and eliminating clear-cutting of forest lands for farmland usage,” said Advanced Container Technologies CEO Doug Heldoorn in the press release. “Additionally, a GrowPod can be set up in a matter of days, so that food shortages can be reduced in just weeks, instead of months or years.”

To view the full press release, visit https://cnw.fm/SB0kL

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%
The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)
Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector
Its management is confident that its research and technology development investment will pay off and provide greater consumer satisfaction.

In 2019, it was estimated that at least 1.1 billion people globally smoked cigarettes regularly. 780 million, representing 71% of the global smoking population, noted that they wanted to quit. Their resolve to quit smoking has seen a significant decline in cigarette sales and a steady rise in nicotine alternatives, which experts project will carry on for the foreseeable future (https://cnw.fm/UyBtW).

For one, the nicotine pouch market has grown significantly and is estimated to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%. The nicotine replacement therapy (“NRT”) market size, on the other hand, is projected to reach $147.9 billion by 2028, representing a CAGR of 16.3% over the 2021 to 2028 forecast period (https://cnw.fm/YyNlg).

Lexaria Bioscience (NASDAQ: LEXX) acknowledges the transference from smoking cigarettes to nicotine alternatives. Through its patented DehydraTECH technology, it looks to tap into this 853 billion dollar industry and stamp its position as the undisputed industry leader.

Since Lexaria began the development of DehydraTECH back in 2014, it has seen its application in various areas, including but not limited to antivirals, cannabinoids, vitamins, and non-steroidal anti-inflammatory drugs (“NSAIDs”). However, nicotine is showing great promise, with Lexaria exploring the oral mucosal nicotine market that is an integral part of the smokeless tobacco products sector which is expected to grow at a CAGR of 7.2% from 2018 to 2025 (https://cnw.fm/Yrt30).

In a move that sought to prove DehydraTECH’s superiority, Lexaria conducted an oral nicotine absorption study in 2021. The research showed that Lexaria’s nicotine delivered via an oral pouch product dispensed enough nicotine levels in blood plasma in four minutes, as concentration-matched controls did in 45 minutes. In addition, peak levels of DehydraTECH nicotine proved to be approximately ten times higher than the peak level of the controls (https://cnw.fm/GNae9).

Lexaria is looking to build on these findings with the latest human study slated to begin in the summer of 2022. The research will compare Lexaria’s DehydraTECH-nicotine pouch performance to existing leading brands on shelves in the United States. The company is optimistic that this study will help it differentiate itself, its brand, and its product in the market, ultimately growing its market share and creating value for its shareholders.

With key industry players such as Altria Group, British American Tobacco Industries, Philip Morris International, and GlaxoSmithKline PLC embracing a transition to a smoke-free future, Lexaria isn’t being left behind. Instead, it recognizes the existing opportunity and is capitalizing on its DehydraTECH technology to set itself apart from its peers and aggressively push its brand in the market.

Lexaria’s management is confident that its research investment and technology development will pay off significantly with time. But, more importantly, they note that it will provide much greater consumer satisfaction.

“Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction,” reckoned Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”).

“Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete,” he added.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.